AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 135 filers reported holding AMYLYX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,474,786 | -15.0% | 681,310 | +0.2% | 0.75% | -5.3% |
Q2 2023 | $14,668,355 | -36.7% | 680,035 | -13.9% | 0.80% | -41.9% |
Q1 2023 | $23,166,600 | -4.3% | 789,591 | +20.5% | 1.37% | -8.7% |
Q4 2022 | $24,202,804 | +82.2% | 655,015 | +38.8% | 1.50% | +78.5% |
Q3 2022 | $13,284,000 | – | 471,887 | – | 0.84% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Perceptive Advisors | 5,472,033 | $154,038,000 | 4.47% |
Ghost Tree Capital, LLC | 550,000 | $15,483,000 | 4.35% |
Ghost Tree Capital, LLC | 500,000 | $14,075,000 | 3.95% |
Bain Capital Life Sciences Investors, LLC | 1,023,214 | $28,803,000 | 3.44% |
Boxer Capital, LLC | 2,084,000 | $58,665,000 | 3.30% |
Alpha Wave Global, LP | 700,635 | $19,723,000 | 2.33% |
Soleus Capital Management, L.P. | 429,336 | $12,086,000 | 1.64% |
Ikarian Capital, LLC | 250,000 | $7,037,000 | 1.40% |
Cormorant Asset Management, LP | 610,000 | $17,172,000 | 1.20% |
SECTORAL ASSET MANAGEMENT INC | 205,400 | $5,782,000 | 1.14% |